Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Scott A Reisman, Sarabjit S Gahir, Chun-Yue I Lee, Joel W Proksch, Mitsumasa Sakamoto & Keith W Ward. (2019) Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates. Drug Design, Development and Therapy 13, pages 1259-1270.
Read now
Read now
Matej Sova & Luciano Saso. (2018) Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review. Drug Design, Development and Therapy 12, pages 3181-3197.
Read now
Read now
Articles from other publishers (32)
Niloufar A. Boghdeh, Kenneth H. Risner, Michael D. Barrera, Clayton M. Britt, David K. Schaffer, Farhang Alem, Jacquelyn A. Brown, John P. Wikswo & Aarthi Narayanan. (2022) Application of a Human Blood Brain Barrier Organ-on-a-Chip Model to Evaluate Small Molecule Effectiveness against Venezuelan Equine Encephalitis Virus. Viruses 14:12, pages 2799.
Crossref
Crossref
Zengxin Jiang, Guobin Qi, Wei Lu, Hao Wang, Defang Li, Weibin Chen, Lei Ding, Xiuying Yang, Hengfeng Yuan & Qingmin Zeng. (2022) Omaveloxolone inhibits IL-1β-induced chondrocyte apoptosis through the Nrf2/ARE and NF-κB signalling pathways in vitro and attenuates osteoarthritis in vivo. Frontiers in Pharmacology 13.
Crossref
Crossref
Yan Zhao, Yuansong Bai, Meili Shen & Yapeng Li. (2022) Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Frontiers in Immunology 13.
Crossref
Crossref
Madleen Zighan, David Arkadir, Liza Douiev, Guy Keller, Chaya Miller & Ann Saada. (2022) Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Adam J. Cohen‐Nowak, Alexa J. Cohen, Emily D. Correia, Carla P. Portocarrero, Andrew P. South & Neda Nikbakht. (2022) Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model. Experimental Dermatology 31:7, pages 1083-1088.
Crossref
Crossref
Adam J. Luginbuhl, Kealan HobelmannJulianna RodinSanket ShuklaUlrich RodeckAlban Linnenbach. (2021)
Synthetic Triterpenoid
RTA
‐408: Limits Radiation Damage to Normal Tissue
. The Laryngoscope 132:6, pages 1196-1204.
Crossref
Crossref
Libin Hu, Yang Cao, Huaijun Chen, Lei Xu, Qiguo Yang, Hang Zhou, Jianru Li, Qian Yu, Zhangqi Dou, Yin Li, Feng Yan, Fuyi Liu & Gao Chen. (2022) The Novel Nrf2 Activator Omaveloxolone Regulates Microglia Phenotype and Ameliorates Secondary Brain Injury after Intracerebral Hemorrhage in Mice. Oxidative Medicine and Cellular Longevity 2022, pages 1-18.
Crossref
Crossref
Zhiguo Ling, Chuan Yang, Jiulin Tan, Ce Dou & Yueqi Chen. (2021) Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases. Cellular and Molecular Life Sciences 78:23, pages 7161-7183.
Crossref
Crossref
Xueman Zhou, Wenxiu Yuan, Xin Xiong, Zhenzhen Zhang, Jiaqi Liu, Yingcheng Zheng, Jun Wang & Jin Liu. (2021) HO-1 in Bone Biology: Potential Therapeutic Strategies for Osteoporosis. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Jia Sun, Jia-Yan Li, Long-Qing Zhang, Dan-Yang Li, Jia-Yi Wu, Shao-Jie Gao, Dai-Qiang Liu, Ya-Qun Zhou & Wei Mei. (2021) Nrf2 Activation Attenuates Chronic Constriction Injury-Induced Neuropathic Pain via Induction of PGC-1α-Mediated Mitochondrial Biogenesis in the Spinal Cord. Oxidative Medicine and Cellular Longevity 2021, pages 1-17.
Crossref
Crossref
Maximillian Taro William Lee, William Mahy & Mark David Rackham. (2021) The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. RSC Medicinal Chemistry 12:8, pages 1281-1311.
Crossref
Crossref
Zhengqi Cheng, Yue Li, Xue Zhu, Ke Wang, Youmna Ali, Wenying Shu, Ting Zhang, Ling Zhu, Michael Murray & Fanfan Zhou. (2021) The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. Planta Medica 87:07, pages 511-527.
Crossref
Crossref
María Belen Cancela, Santiago Zugbi, Ursula Winter, Ana Laura Martinez, Claudia Sampor, Mariana Sgroi, Jasmine H. Francis, Ralph Garippa, David H. Abramson, Guillermo Chantada & Paula Schaiquevich. (2020) A decision process for drug discovery in retinoblastoma. Investigational New Drugs 39:2, pages 426-441.
Crossref
Crossref
Stephanie Kourakis, Cara A. Timpani, Dean G. Campelj, Patricia Hafner, Nuri Gueven, Dirk Fischer & Emma Rybalka. (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Paul S. Baxter, Nóra M. Márkus, Owen Dando, Xin He, Bashayer R. Al-Mubarak, Jing Qiu & Giles E. Hardingham. (2021) Targeted de-repression of neuronal Nrf2 inhibits α-synuclein accumulation. Cell Death & Disease 12:2.
Crossref
Crossref
Jianjun Deng, Jianbo Xiao & Haixia Yang. 2021. Handbook of Dietary Phytochemicals. Handbook of Dietary Phytochemicals
423
475
.
Mohd Rehan, Shafiullah & Sameer A. Mir. (2020) Structural diversity, natural sources, and pharmacological potential of plant-based saponins with special focus on anticancer activity: a review. Medicinal Chemistry Research 29:10, pages 1707-1722.
Crossref
Crossref
Yufei Wang, Anna Jia, Yujing Bi, Yuexin Wang, Qiuli Yang, Yejin Cao, Yan Li & Guangwei Liu. (2020) Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Cancers 12:9, pages 2626.
Crossref
Crossref
Paola De Cicco, Giuseppe Ercolano & Angela Ianaro. (2020) The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Frontiers in Immunology 11.
Crossref
Crossref
Sharadha Dayalan Naidu & Albena T. Dinkova-Kostova. (2020) KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease. Open Biology 10:6.
Crossref
Crossref
Emiliano Panieri, Aleksandra Buha, Pelin Telkoparan-Akillilar, Dilek Cevik, Demetrios Kouretas, Aristidis Veskoukis, Zoi Skaperda, Aristidis Tsatsakis, David Wallace, Sibel Suzen & Luciano Saso. (2020) Potential Applications of NRF2 Modulators in Cancer Therapy. Antioxidants 9:3, pages 193.
Crossref
Crossref
Xuewu Sun, Ziang Xie, Bin Hu, Boya Zhang, Yan Ma, Xin Pan, Hai Huang, Jiying Wang, Xiangde Zhao, Zhiwei Jie, Peihua Shi & Zhijun Chen. (2020) The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling. Redox Biology 28, pages 101309.
Crossref
Crossref
Volkmar Weissig. (2020) Drug Development for the Therapy of Mitochondrial Diseases. Trends in Molecular Medicine 26:1, pages 40-57.
Crossref
Crossref
Sandeep & Sumit Ghosh. 2020. Bioactive Natural Products. Bioactive Natural Products
411
461
.
Jianjun Deng, Jianbo Xiao & Haixia Yang. 2020. Handbook of Dietary Phytochemicals. Handbook of Dietary Phytochemicals
1
53
.
Fatih M. Uckun & Sanjive Qazi. 2020. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
343
360
.
Christian Bailly. (2019) Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers. International Immunopharmacology 77, pages 105967.
Crossref
Crossref
Wenxin Wang, Xueli Xia, Lingxiang Mao & Shengjun Wang. (2019) The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function. Frontiers in Immunology 10.
Crossref
Crossref
Larissa Staurengo-Ferrari, Stephanie Badaro-Garcia, Miriam S. N. Hohmann, Marília F. Manchope, Tiago H. Zaninelli, Rubia Casagrande & Waldiceu A. VerriJr.Jr.. (2019) Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages. Frontiers in Pharmacology 9.
Crossref
Crossref
Keith S. Wong & Walid A. Houry. 2019. Mitochondria in Health and in Sickness. Mitochondria in Health and in Sickness
119
142
.
Fatih M. Uckun & Sanjive Qazi. 2018. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
1
18
.
Rosella Abeti, Annalisa Baccaro, Noemi Esteras & Paola Giunti. (2018) Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models. Frontiers in Cellular Neuroscience 12.
Crossref
Crossref